KakaoPay Securities, Dinari, and Ondo Finance are exploring an initiative to tokenize Korean stocks, potentially allowing equity exposure through blockchain tokens. This exploratory project aims to expand regulated on-chain equity access in South Korea's retail market but has no confirmed product launch, regulatory approval, or partnership agreements yet. Key issues include legal structure, investor protections, custody models, and cross-border participation. The initiative remains conceptual, with progress dependent on regulatory clearance and formal pilot announcements.
KakaoPay Securities, Dinari, and Ondo's exploration of Korean stock tokenization provides context for digital asset interest. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Sep 30, 2026 04:03 WIB: out of 50 major cryptocurrencies, 29 rose and 20 fell today. Notable movers include ALGO at Rp2.271 with a 1-day change of -6.47%, SUSHI at Rp4.785 up 5.85%, and SNX at Rp4.589 up 5.18%.
GameStop's CEO Ryan Cohen and other executives have made significant insider purchases of millions of shares, showing strong confidence in the company's future despite recent stock price volatility. These buys were active decisions, not pre-scheduled...
Concentrix Corporation reported mixed Q3 2026 results with earnings per share of $2.92, beating analyst expectations of $2.71. However, its revenue of $2.45 billion slightly missed the forecast of $2.48 billion. The company achieved a record free cas...
Accenture is set to report Q3 2026 earnings on October 1, with analysts forecasting $18.03 billion in revenue, a 5.6% increase year-over-year, and earnings per share around $3.18. The growth is fueled by strong demand for AI services, with 100 new ad...
Iovance Biotherapeutics shares jumped 31.48% after raising its 2026 revenue forecast, driven by strong demand for its cancer immunotherapy Amtagvi. SoundThinking's stock rose 50.09% following an acquisition agreement with Transom Capital Group, offer...
Shares of uniQure dropped 37.33% following mixed clinical data for its Huntington's disease gene therapy. Fair Isaac fell 26.52% after U.S. regulators expanded the use of competitor VantageScore in mortgage credit scoring, threatening its market posi...
